Shashitha Gavini, DO
Cardiovascular Disease · Baton Rouge, LANPI 1376074179
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.3% of the total across 144 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 16.9% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,744, more than ten times the $83 reported in 2019.
Across 144 payments — averaging $40.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$992
- Abbott$941
- Kestra Medical Technology Services, Inc.$804
- Medtronic$763
- Abiomed$277
- Pfizer$172
- plus $2K from 27 others
What the payments were for
- Food & beverage$5,64396%
- Education$2164%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 20 | $992 |
| Abbott | 29 | $941 |
| Kestra Medical Technology Services, Inc. | 17 | $804 |
| Medtronic | 9 | $763 |
| Abiomed | 7 | $277 |
| Pfizer | 5 | $172 |
| Edwards Lifesciences | 2 | $162 |
| Bard Peripheral Vascular, Inc. | 1 | $160 |
| Endologix LLC | 1 | $148 |
| AstraZeneca | 10 | $145 |
| Cardiovascular Systems Inc. | 1 | $140 |
| Penumbra, Inc. | 1 | $137 |
| Shockwave Medical, Inc | 1 | $125 |
| Itamar Medical Inc | 2 | $114 |
| Daiichi Sankyo Inc. | 5 | $106 |
| Scpharmaceuticals Inc. | 6 | $99 |
| E.r. Squibb & Sons, L.L.C. | 6 | $86 |
| Otsuka America Pharmaceutical, Inc. | 1 | $83 |
| Inspire Medical Systems, Inc. | 2 | $55 |
| Cardiac Dimensions, Inc. | 1 | $51 |
| Merck | 3 | $45 |
| Bayer | 2 | $43 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $39 |
| Cardiva Medical, Inc. | 1 | $23 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $21 |
| Atricure, Inc. | 1 | $20 |
| Johnson & Johnson | 1 | $18 |
| Esperion Therapeutics, Inc. | 1 | $17 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
| Boston Scientific | 1 | $15 |
| Lexicon Pharmaceuticals, Inc. | 1 | $14 |
| Boehringer Ingelheim | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Repatha$593
- COREVALVE EVOLUT R$331
- ENSITE$216
- SYMPLICITY G3$172
- VENOVO$160
- Assure WCD$156
- ENDOCROSS Device$148
- Torus Stent Graft System$148
- Impella$141
- Diamondback Peripheral$140
- Diamondback Coronary$140
- Indigo System$137
- EVOQUE$134
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$125
- AVEIR$110
- LINQ II$105
- WatchPATONE$104
- VYNDAQEL$100
How this compares
$5,859 in reported general payments places this provider in the 60th percentile of 281 cardiovascular disease providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 59 | $53,820 |
| EliquisApixaban | 46 | $47,086 |
| FarxigaDapagliflozin Propanediol | 41 | $34,453 |
| JardianceEmpagliflozin | 47 | $32,060 |
| XareltoRivaroxaban | 12 | $6,490 |
| Atorvastatin Calcium | 165 | $1,530 |
| Metoprolol Succinate | 147 | $1,377 |
| Bumetanide | 42 | $893 |
| Potassium Chloride | 42 | $750 |
| Nifedipine ErNifedipine | 42 | $692 |
| Ezetimibe | 43 | $640 |
| Carvedilol | 64 | $553 |
| Amlodipine Besylate | 99 | $515 |
| ClopidogrelClopidogrel Bisulfate | 28 | $354 |
| Losartan Potassium | 33 | $335 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $172 | $47,08646 claims |
| AstraZenecaFarxiga | $145 | $34,45341 claims |
| Boehringer IngelheimJardiance | $14 | $32,06047 claims |
| Johnson & JohnsonXarelto | $18 | $6,49012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 281 cardiovascular disease providers in Louisiana.
Other cardiovascular disease in Baton Rouge
- George KaramBaton Rouge$110K
- Federico DepuyBaton Rouge$68K
- Tara JarreauBaton Rouge$62K
- James BarriosBaton Rouge$43K
- Paul GarrettBaton Rouge$24K
- Cordel ParrisBaton Rouge$24K
- Steven GremillionBaton Rouge$12K
- Curley BordelonBaton Rouge$12K
- Nakia NewsomeBaton Rouge$12K
- Kiran GarikapatiBaton Rouge$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.